13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001346824
Total reported value
$11.5B
$11.5B
67 檔
32.6%
The Q3 2025 SEC filing reveals that Ra Capital Management, L.p. held a total portfolio value of $11.5B, covering 67 public equity positions.
In Q3 2025, Ra Capital Management, L.p. adopted a defensive or profit-taking posture, trimming 5 positions and completely liquidating 37 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ASND | Ascendis Pharma A/S | Stock-Other | 25.19% | -24.92% | EXIT | |
| 2 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 7.07% | +0.29% | +2.16% | |
| 3 | PCVX | Vaxcyte Inc | Stock-Other | 5.31% | -1.27% | — | |
| 4 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 4.64% | — | +18.92% | |
| 5 | CDTX | Cidara Therapeutics Inc | Stock-Other | 3.97% | — | — | |
| 6 | SION | Sionna Therapeutics Inc | Stock-Other | 3.79% | -0.42% | — | |
| 7 | ETNBGBP | 89bio Inc | Stock-Other | 3.60% | — | — | |
| 8 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 3.55% | -0.43% | — | |
| 9 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 3.42% | -0.41% | +19.14% | |
| 10 | JANX | Janux Therapeutics Inc | Stock-Other | 3.37% | -0.16% | — | |
| 11 | ACLXGBX | Arcellx Inc | Stock-Other | 3.07% | — | — | |
| 12 | LENZ | Lenz Therapeutics Inc | Stock-Other | 2.40% | -0.20% | — | |
| 13 | TYRA | Tyra Biosciences Inc | Stock-Other | 2.10% | -1.56% | — | |
| 14 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.08% | -0.52% | +5.31% | |
| 15 | WVE | Wave Life Sciences Ltd. | Stock-Other | 1.64% | -0.71% | — | |
| 16 | SEPN | Septerna Inc | Stock-Other | 1.62% | +0.26% | — | |
| 17 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.39% | -2.32% | EXIT | |
| 18 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.35% | +0.34% | — | |
| 19 | GHRS | GH Research PLC | Stock-Other | 1.35% | +0.64% | — | |
| 20 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 1.34% | -0.16% | — | |
| 21 | NUVL | Nuvalent Inc-a | Stock-Other | 1.33% | -1.41% | — | |
| 22 | IRON | Disc Medicine Inc | Stock-Other | 1.28% | -0.10% | — | |
| 23 | VOR | Vor Biopharma Inc | Stock-Other | 1.19% | -0.64% | — | |
| 24 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 1.16% | -0.49% | EXIT | |
| 25 | PEPG | Pepgen Inc | Stock-Other | 1.14% | -0.07% | +87.70% | |
| 26 | GERN | Geron CORP | Stock-Other | 1.02% | -0.53% | — | |
| 27 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.95% | +0.27% | — | |
| 28 | BLTE | Belite Bio Inc - Adr | Stock-Other | 0.80% | — | — | |
| 29 | CLYM | Climb Bio Inc | Stock-Other | 0.78% | +0.46% | — | |
| 30 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.54% | — | +2.67% | |
| 31 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.52% | — | — | |
| 32 | MNPR | Monopar Therapeutics Inc | Stock-Other | 0.51% | +0.15% | — | |
| 33 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.49% | +0.08% | — | |
| 34 | SLDB | Solid Biosciences Inc | Stock-Other | 0.44% | +0.33% | +0.00% | |
| 35 | ✓ | Stock-Other | 0.44% | — | — | ||
| 36 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 0.35% | +0.84% | — | |
| 37 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 0.35% | +0.04% | — | |
| 38 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.34% | -0.24% | EXIT | |
| 39 | ASMB | Assembly Biosciences Inc | Stock-Other | 0.32% | -0.06% | — | |
| 40 | ABOS | Acumen Pharmaceuticals Inc | Stock-Other | 0.31% | -0.03% | — | |
| 41 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 0.31% | -0.18% | EXIT | |
| 42 | NKTX | Nkarta Inc | Stock-Other | 0.28% | +0.03% | — | |
| 43 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.24% | — | — | |
| 44 | IVVD | Invivyd Inc | Stock-Other | 0.23% | — | — | |
| 45 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.21% | — | — | |
| 46 | PRME | Prime Medicine Inc | Stock-Other | 0.20% | — | — | |
| 47 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.19% | — | — | |
| 48 | ACRV | Acrivon Therapeutics Inc | Stock-Other | 0.19% | +0.07% | — | |
| 49 | HOWL | Werewolf Therapeutics Inc | Stock-Other | 0.16% | -0.05% | — | |
| 50 | QURE | uniQure N.V. | Stock-Other | 0.14% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CDTX | Cidara Therapeutics Inc | +3.6% | — | Add |
| 2 | SION | Sionna Therapeutics Inc | +2% | — | Unchanged |
| 3 | MLYS | Mineralys Therapeutics Inc | +1.8% | +19.14% | Add |
| 4 | RYTM | Rhythm Pharmaceuticals Inc | +1.7% | +2.16% | Trim |
| 5 | RNAGBP | Avidity Biosciences Inc | +1.5% | +18.92% | Add |
| 6 | ETNBGBP | 89bio Inc | +1.2% | — | Unchanged |
| 7 | SEPN | Septerna Inc | +0.9% | — | Unchanged |
| 8 | PEPG | Pepgen Inc | +0.9% | +87.70% | Add |
| 9 | TSHA | Taysha Gene Therapies Inc | +0.7% | — | Add |
| 10 | FULC | Fulcrum Therapeutics Inc | +0.7% | — | Unchanged |
| 11 | LENZ | Lenz Therapeutics Inc | +0.6% | — | Unchanged |
| 12 | DNTH | Dianthus Therapeutics Inc | +0.5% | — | Unchanged |
| 13 | TYRA | Tyra Biosciences Inc | +0.5% | — | Add |
| 14 | FDMT | 4d Molecular Therapeutics In | +0.2% | — | Unchanged |
| 15 | MNPR | Monopar Therapeutics Inc | +0.2% | — | Unchanged |
| 16 | SLDB | Solid Biosciences Inc | +0.2% | +0.00% | Add |
| 17 | CLYM | Climb Bio Inc | +0.1% | — | Unchanged |
| 18 | ✓ | +0.1% | — | Unchanged | |
| 19 | CTMX | Cytomx Therapeutics Inc | +0.1% | — | Add |
| 20 | NAMS | NewAmsterdam Pharma Company N.V. | +0.1% | — | Unchanged |
| 21 | GPCR | Structure Therapeutics Inc | +0.1% | — | Unchanged |
| 22 | GHRS | GH Research PLC | +0.1% | — | Add |
| 23 | HOWL | Werewolf Therapeutics Inc | +0.1% | — | Add |
| 24 | ABOS | Acumen Pharmaceuticals Inc | 0% | — | Unchanged |
| 25 | RCUS | Arcus Biosciences Inc | 0% | — | Unchanged |
| 26 | LRMR | Larimar Therapeutics Inc | 0% | — | Unchanged |
| 27 | ✓ | Newamsterdam Pharma Company | 0% | — | Unchanged |
| 28 | TVTX | Travere Therapeutics Inc | — | — | Unchanged |
| 29 | TORCEUR | Adicet Bio Inc | 0% | — | Unchanged |
| 30 | IRON | Disc Medicine Inc | 0% | — | Unchanged |
| 31 | AVTX | Avalo Therapeutics Inc | 0% | -28.94% | Trim |
| 32 | ✓ | 0% | — | Unchanged | |
| 33 | SRZN | Surrozen Inc | 0% | — | Trim |
| 34 | NKTX | Nkarta Inc | -0.1% | — | Unchanged |
| 35 | SRRK | Scholar Rock Holding CORP | -0.1% | +2.67% | Add |
| 36 | ELDN | Eledon Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 37 | ACRV | Acrivon Therapeutics Inc | -0.1% | — | Unchanged |
| 38 | ARTV | Artiva Biotherapeutics Inc | -0.1% | — | Unchanged |
| 39 | BCAX | Bicara Therapeutics Inc | -0.2% | — | Unchanged |
| 40 | ACLXGBX | Arcellx Inc | -0.3% | — | Unchanged |
| 41 | GKOS | Glaukos CORP | -0.3% | — | Trim |
| 42 | GERN | Geron CORP | -0.6% | — | Unchanged |
| 43 | WVE | Wave Life Sciences Ltd. | -0.8% | — | Unchanged |
| 44 | SPRY | Ars Pharmaceuticals Inc | -0.9% | — | Unchanged |
| 45 | EWTX | Edgewise Therapeutics Inc | -1.2% | +5.31% | Add |
| 46 | ASND | Ascendis Pharma A/S | -1.6% | — | Unchanged |
| 47 | JANX | Janux Therapeutics Inc | -1.7% | — | Unchanged |
| 48 | PCVX | Vaxcyte Inc | -2.4% | — | Trim |
| 49 | NUVL | Nuvalent Inc-a | — | NEW | New buy |
| 50 | DYN | Dyne Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Ra Capital Management, L.p. reported a total U.S. public equity portfolio value of $11.5B across 67 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ASND, RYTM, PCVX) accounted for 32.6% of total reported equity market value during Q3 2025.
Top New Position Initiated
NUVL
市值: $107.8M
Top Position Liquidated / Trimmed
DYN
前期市值: $101.6M
During Q3 2025, Ra Capital Management, L.p.'s top holdings by market value included ASND (25.2%)、RYTM (7.1%)、PCVX (5.3%). The largest single position, ASND, represented 25.2% of total portfolio value.
In Q3 2025, Ra Capital Management, L.p. made 73 total portfolio adjustments, initiating 19 new buys, adding to 12 positions, trimming 5 holdings, and fully liquidating 37 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.